When Software Replaces Springs: Closed-Loop Delivery for Next-Generation Biologics

Session details:

1. The limits of mechanical injection: As biologics continue to increase in volume and viscosity, traditional spring-powered injector architectures are approaching their performance limits, particularly for subcutaneous delivery of volumes greater than 5 mL. 
2. Why closed-loop control changes the equation: Software-driven, closed-loop delivery enables real-time control of injection parameters, expanding the range of drug formulations, primary containers, and delivery profiles that can be administered reliably in the home.
3. From devices to platforms: Software-configurable delivery platforms reduce development risk, create optionality across multiple therapeutic assets, and improve the patient experience. They enable pharmaceutical companies to build scalable delivery strategies that maximize portfolio value.